FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547792004> ?p ?o ?g. }

• W2547792004 endingPage "393" @default.
• W2547792004 startingPage "393" @default.
• W2547792004 abstract "Endocrine therapy using estrogen receptor-α (ER-α) antagonists for attenuating horm2one-driven cell proliferation is a major treatment modality for breast cancers. To exploit any DNA repair deficiencies associated with endocrine therapy, we investigated the functional and physical interactions of ER-α with O6-methylguanine DNA methyltransferase (MGMT), a unique DNA repair protein that confers tumor resistance to various anticancer alkylating agents. The ER-α -positive breast cancer cell lines (MCF-7, T47D) and ER- negative cell lines (MDAMB-468, MDAMB-231), and established inhibitors of ER-α and MGMT, namely, ICI-182,780 (Faslodex) and O6-benzylguanine, respectively, were used to study MGMT- ER interactions. The MGMT gene promoter was found to harbor one full and two half estrogen-responsive elements (EREs) and two antioxidant-responsive elements (AREs). MGMT expression was upregulated by estrogen, downregulated by tamoxifen in Western blot and promoter-linked reporter assays. Similarly, both transient and stable transfections of Nrf-2 (nuclear factor-erythroid 2-related factor-2) increased the levels of MGMT protein and activity 3 to 4-fold reflecting novel regulatory nodes for this drug-resistance determinant. Of the different ER-α antagonists tested, the pure anti-estrogen fulvestrant was most potent in inhibiting the MGMT activity in a dose, time and ER-α dependent manner, similar to O6-benzylguanine. Interestingly, fulvestrant exposure led to a degradation of both ER-α and MGMT proteins and O6-benzylguanine also induced a specific loss of ER-α and MGMT proteins in MCF-7 and T47D breast cancer cells with similar kinetics. Immunoprecipitation revealed a specific association of ER-α and MGMT proteins in breast cancer cells. Furthermore, silencing of MGMT gene expression triggered a decrease in the levels of both MGMT and ER-α proteins. The involvement of proteasome in the drug-induced degradation of both proteins was also demonstrated. Fulvestrant enhanced the cytotoxicity of MGMT-targeted alkylating agents, namely, temozolomide and BCNU by 3 to 4-fold in ER-α positive cells, but not in ER–negative cells. We conclude that MGMT and ER-α proteins exist as a complex and are co-targeted for ubiquitin-conjugation and subsequent proteasomal degradation. The findings offer a clear rationale for combining alkylating agents with endocrine therapy." @default.
• W2547792004 created "2016-11-11" @default.
• W2547792004 creator A5004785534 @default.
• W2547792004 creator A5015226138 @default.
• W2547792004 creator A5028881108 @default.
• W2547792004 creator A5031290956 @default.
• W2547792004 creator A5033003394 @default.
• W2547792004 creator A5066473505 @default.
• W2547792004 creator A5067903216 @default.
• W2547792004 creator A5068063508 @default.
• W2547792004 creator A5068931556 @default.
• W2547792004 creator A5079168766 @default.
• W2547792004 creator A5081835857 @default.
• W2547792004 date "2016-01-01" @default.
• W2547792004 modified "2023-10-05" @default.
• W2547792004 title "New insights into estrogenic regulation of O6-methylguanine DNA-methyltransferase (MGMT) in human breast cancer cells: Co-degradation of ER-α and MGMT proteins by fulvestrant or O6-benzylguanine indicates fresh avenues for therapy" @default.
• W2547792004 cites W1026119132 @default.
• W2547792004 cites W1538045376 @default.
• W2547792004 cites W1911801098 @default.
• W2547792004 cites W1976052037 @default.
• W2547792004 cites W1981206419 @default.
• W2547792004 cites W1985850066 @default.
• W2547792004 cites W1988299559 @default.
• W2547792004 cites W1988877375 @default.
• W2547792004 cites W1992244344 @default.
• W2547792004 cites W1999220209 @default.
• W2547792004 cites W1999469178 @default.
• W2547792004 cites W1999549596 @default.
• W2547792004 cites W2002015567 @default.
• W2547792004 cites W2004392534 @default.
• W2547792004 cites W2010511761 @default.
• W2547792004 cites W2013809140 @default.
• W2547792004 cites W2015629450 @default.
• W2547792004 cites W2016275660 @default.
• W2547792004 cites W2018342610 @default.
• W2547792004 cites W2018397818 @default.
• W2547792004 cites W2019243649 @default.
• W2547792004 cites W2022686839 @default.
• W2547792004 cites W2024981819 @default.
• W2547792004 cites W2025002326 @default.
• W2547792004 cites W2030067938 @default.
• W2547792004 cites W2030676208 @default.
• W2547792004 cites W2037916186 @default.
• W2547792004 cites W2047673434 @default.
• W2547792004 cites W2055621384 @default.
• W2547792004 cites W2059457785 @default.
• W2547792004 cites W2072339938 @default.
• W2547792004 cites W2077367075 @default.
• W2547792004 cites W2081491080 @default.
• W2547792004 cites W2082026833 @default.
• W2547792004 cites W2093116072 @default.
• W2547792004 cites W2101063496 @default.
• W2547792004 cites W2105269188 @default.
• W2547792004 cites W2108573302 @default.
• W2547792004 cites W2112444654 @default.
• W2547792004 cites W2115831753 @default.
• W2547792004 cites W2116397033 @default.
• W2547792004 cites W2120884178 @default.
• W2547792004 cites W2121454015 @default.
• W2547792004 cites W2126602665 @default.
• W2547792004 cites W2131199058 @default.
• W2547792004 cites W2136600170 @default.
• W2547792004 cites W2142427369 @default.
• W2547792004 cites W2142992540 @default.
• W2547792004 cites W2146899967 @default.
• W2547792004 cites W2151164163 @default.
• W2547792004 cites W2151230162 @default.
• W2547792004 cites W2151989609 @default.
• W2547792004 cites W2224089884 @default.
• W2547792004 cites W2411335118 @default.
• W2547792004 cites W2417418092 @default.
• W2547792004 cites W4235221123 @default.
• W2547792004 doi "https://doi.org/10.7555/jbr.30.20160040" @default.
• W2547792004 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5044712" @default.
• W2547792004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27845303" @default.
• W2547792004 hasPublicationYear "2016" @default.
• W2547792004 type Work @default.
• W2547792004 sameAs 2547792004 @default.
• W2547792004 citedByCount "12" @default.
• W2547792004 countsByYear W25477920042018 @default.
• W2547792004 countsByYear W25477920042019 @default.
• W2547792004 countsByYear W25477920042020 @default.
• W2547792004 countsByYear W25477920042021 @default.
• W2547792004 countsByYear W25477920042022 @default.
• W2547792004 countsByYear W25477920042023 @default.
• W2547792004 crossrefType "journal-article" @default.
• W2547792004 hasAuthorship W2547792004A5004785534 @default.
• W2547792004 hasAuthorship W2547792004A5015226138 @default.
• W2547792004 hasAuthorship W2547792004A5028881108 @default.
• W2547792004 hasAuthorship W2547792004A5031290956 @default.
• W2547792004 hasAuthorship W2547792004A5033003394 @default.
• W2547792004 hasAuthorship W2547792004A5066473505 @default.
• W2547792004 hasAuthorship W2547792004A5067903216 @default.
• W2547792004 hasAuthorship W2547792004A5068063508 @default.
• W2547792004 hasAuthorship W2547792004A5068931556 @default.
• W2547792004 hasAuthorship W2547792004A5079168766 @default.
• W2547792004 hasAuthorship W2547792004A5081835857 @default.
• W2547792004 hasBestOaLocation W25477920041 @default.

• next